江蘇新能(603693.SH):參股公司協聯生物質完成註銷登記
格隆匯1月13日丨江蘇新能(603693.SH)公佈,江蘇國信協聯生物質發電有限公司(以下簡稱“協聯生物質”)是公司的參股公司,江蘇新能及國聯信託股份有限公司分別持有其50%的股權。協聯生物質註冊資本人民幣3000萬元,經營範圍為生物質發電;秸稈、樹枝、樹皮回收;灰渣、脱硫石膏銷售,自成立以來未開展實質性生產經營活動,股東未實際繳納出資。經協聯生物質各股東協商,決定對該公司進行註銷處理。
近日,公司收到協聯生物質的通知,其已收到宜興市市場監督管理局出具的《公司准予註銷登記通知書》,協聯生物質註銷登記手續辦理完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.